Gut microbiota and stroke: immune priming before brain injury

Gut microbiota and stroke may be connected before brain injury even begins. A study in Cell shows in mice that a molecule made by intestinal bacteria can precondition immune cells and alter the severity of a later ischemic stroke.

That timing is what makes the finding particularly interesting. A stroke begins when blood flow to part of the brain is interrupted, but the immune response that follows may already have been shaped elsewhere in the body.

A signal generated in the gut

The molecule at the center of the study is indole, a small metabolite produced when certain gut bacteria break down the amino acid tryptophan. Bacteria need the tnaA gene to perform this reaction, and some strains of Escherichia coli carry the required machinery.

The researchers used a mouse model of ischemic stroke based on transient middle cerebral artery occlusion. Animals with more severe strokes had a different ileal microbial profile, including an enrichment of bacteria capable of producing indole.

The team then moved beyond association.

Giving mice indole before stroke increased brain infarct volume and neurological deficits. Mice colonized with an E. coli strain unable to produce indole developed less severe injury than animals colonized with an indole-producing strain.

That distinction mattered. The relevant feature was not simply the presence of E. coli, but a specific microbial metabolic function.

How indole redirected immune cells

The next step of the pathway involved the intestinal immune system.

Indole can activate the aryl hydrocarbon receptor, or AHR, a cellular sensor that responds to a variety of small molecules derived from diet, the environment, and microbes. Activating AHR can change which genes a cell uses and therefore how that cell behaves.

The researchers focused on dendritic cells, immune cells that sample their surroundings and help coordinate subsequent immune responses.

When AHR was selectively deleted from these cells, mice had better stroke outcomes. The dendritic cells also adopted transcriptional programs associated with increased migration and immune regulation.

CCR7, a receptor that helps guide immune-cell movement, emerged as part of this change. With reduced AHR signaling, intestinal dendritic cells became more migratory and accumulated in the meninges, the membranes surrounding the brain.

Another change followed there: regulatory T cells, or Tregs, became more abundant. These cells can restrain excessive inflammatory responses.

Pharmacological AHR inhibition produced a similar pattern, with more gut-derived dendritic cells in the meninges, increased meningeal Tregs, and reduced neuroinflammation. When the researchers experimentally depleted Tregs, the early protective effect of AHR inhibition disappeared.

The experiments therefore connected several steps: a microbial metabolite in the intestine, a receptor in dendritic cells, altered immune-cell migration, a regulatory T-cell response near the brain, and ultimately the severity of experimental stroke.

The team also transplanted gut microbiota from stroke patients into antibiotic-treated mice. The harmful effects of patient-derived microbiota were attenuated in animals lacking AHR in dendritic cells. The same was true for the detrimental effects of indole itself and indole-producing E. coli, further strengthening the proposed pathway in the mouse model.

What the human data show

The evidence in people is more cautious.

Human metagenomic analyses found E. coli and the bacterial tnaA gene enriched in people with ischemic stroke compared with controls. In a smaller patient analysis, higher fecal indole was associated with more severe neurological deficits.

Higher tnaA abundance was also associated with an unfavorable functional outcome 90 days after stroke in the initial statistical analysis.

But that association weakened after adjustment for clinical factors. tnaA still showed a strong trend, but it was no longer statistically significant as an independent predictor of poor outcome. E. coli abundance itself was no longer associated with outcome after adjustment.

That distinction is central to interpreting the study. The causal pathway was demonstrated experimentally in mice. In humans, the microbiome findings are associations and do not yet show that microbial indole determines stroke severity.

The work therefore does not establish a clinical microbiome test, nor does it show that probiotics, dietary manipulation, or another microbiome intervention can improve stroke outcomes. The authors also note the need for larger prospective human cohorts and experiments in female animals.

The broader result is that, at least in mice, part of the immune response to a future stroke can be programmed before cerebral blood flow is ever interrupted. The chain begins in the gut, passes through a bacterial metabolite and intestinal immune cells, and becomes visible only later when the brain is injured.